Cargando…
Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
BACKGROUND: Stereotactic body radiation therapy (SBRT) and tyrosine kinase inhibitors (TKIs) are effective treatments for metastatic renal cell carcinoma, but data on combining these two modalities are scarce. We aimed to investigate the survival outcomes of SBRT plus TKIs. METHODS: Data of patients...
Autores principales: | Liu, Yang, Zhang, Zhiling, Han, Hui, Guo, Shengjie, Liu, Zhuowei, Liu, Mengzhong, Zhou, Fangjian, Dong, Pei, He, Liru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937906/ https://www.ncbi.nlm.nih.gov/pubmed/33692951 http://dx.doi.org/10.3389/fonc.2021.607595 |
Ejemplares similares
-
Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020) -
Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma
por: Liu, Yang, et al.
Publicado: (2021) -
Survival Outcomes and Prognostic Analysis Following Greater Cytoreductive Radiotherapy in Patients With Metastatic Prostate Cancer
por: Zhang, Zitong, et al.
Publicado: (2020) -
Metastasis-directed stereotactic body radiotherapy for oligometastatic renal cell carcinoma: extent of tumor burden eradicated by radiotherapy
por: Liu, Yang, et al.
Publicado: (2021) -
Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)